Excess Returns

The Resilience No One Trusts | Brent Donnelly on Why War and Oil Haven’t Broken This Market

The Bear Market No One Sees | Liz Ann Sonders on the Real Story Indexes Hide

The Forever Invariable Truth | Jim Grant on War, Inflation, and What Comes Next

The Market the Tweets Can’t Break | What the Options Market Tells Us About What Comes Next

The Risk at the End of the Whip | GMO’s Tom Hancock on Finding Conviction Amid the AI Hype

The Walmart Indicator Just Hit 2008 Levels | Jim Paulsen on the Big Difference This Time

The Inevitability No One Sees | $11 Billion Tech Manager on What Investors Miss About AI

Tony Wang, who runs the T. Rowe Price Science and Technology Fund, joins the podcast to discuss tech investing, AI, and the concept of investing in inevitabilities. Wang believes AI is the dominant driver in the market, leading to a K-shaped distribution where companies are either AI winners or losers. He views the cur...

The Signal Before the Spike | Katie Stockton on What the Charts Tell Us About What Comes Next

Michael Mauboussin | AI, Base Rates, and Investing in the New Economy

The Stagflation Regime | Aahan Menon on What Works When Stocks and Bonds Don’t

6x Earnings. 10x Potential. | Harris Kupperman on the Inflections Wall Street Misses

The Moment Common Knowledge Changed | Last Call - With Andy Constan, Ben Hunt, Brent Kochuba and Eric Pachman

The Private Credit Apocalypse That Isn’t Coming | Larry Swedroe Dispels the Myths

Nothing Is Priced In | Bob Elliott on Why Investors Are Misreading the Oil Shock

You Couldn’t Take Out Amazon with $50 Billion | The 100 Year Thinkers on Why Outliers Drive Returns

Big Decline. Options Support Gone | Brent Kochuba on the Fragile Market Setup

The War Markets Can't Price | Jared Dillian on the Regime Change Investors Miss

They Call It a Lottery Ticket. The Data Says Otherwise | D.A. Wallach on The Hidden Alpha of Biotech

The podcast explores biotech investing, particularly the factors that contribute to active alpha in the space. Venture capitalist D.A. Wallach explains that valuing biotech companies requires domain-specific expertise due to the uncertainty of products reaching the market. He introduces a bag-of-options framework, emph...

14% for Tech. 1% for Everyone Else | The Weekly Wrap – 3/14/2026

The $1 Trillion Supercycle Hidden in Plain Sight | Joseph Shaposhnik